WO1998007743A1 - Macrolides - Google Patents

Macrolides Download PDF

Info

Publication number
WO1998007743A1
WO1998007743A1 PCT/EP1997/004563 EP9704563W WO9807743A1 WO 1998007743 A1 WO1998007743 A1 WO 1998007743A1 EP 9704563 W EP9704563 W EP 9704563W WO 9807743 A1 WO9807743 A1 WO 9807743A1
Authority
WO
WIPO (PCT)
Prior art keywords
sanglifehrin
seco
compound
sanglifehrins
compounds
Prior art date
Application number
PCT/EP1997/004563
Other languages
French (fr)
Inventor
Theodor Fehr
Lukas Oberer
Valérie QUESNIAUX RYFFEL
Jean-Jacques Sanglier
Walter Schuler
Richard Sedrani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to AU43807/97A priority Critical patent/AU4380797A/en
Publication of WO1998007743A1 publication Critical patent/WO1998007743A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to macrohdes, in particular to new compounds belonging to the Sanglifehrin class of compounds.
  • the Sanglifehrins are a recently discovered class of macrolide compounds having immunosuppressive and antiinflammatory activities.
  • the Sanglifehrins are generally described and claimed, together with their pharmaceutical uses, in our copending International Patent Application WO 97/02285, the relevant disclosure of which is incorporated herein by reference.
  • the Sanglifehrins have a characteristic polycyclic macrolide structure as may be seen, for instance, in the structure of Sanglifehrins A, one of the first Sanglifehrins to be isolated from actinomycete fermentation broths, shown below.
  • the present invention provides a Sanglifehrin selected from Sanglifehrins E, F, G, H, I, K and L, Seco-sanglifehrins A, B and C, 53-Dihydro- sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A and 1 ,-Methoxy- seco-sanglifehrin A in free or protected form or a salt thereof.
  • the compounds of the invention are in isolated form, or in pure or substantially pure form (i.e. in a form in which the sanglifehrin content thereof is at least 80%, preferably at least 90%, especially at least 95%, or more especially at least 98%, of the Sanglifehrin in question, e.g. in a form comprising less than 20%, preferably less than 10%, especially less than 5%, or more especially less than 2%, of other Sanglifehrins).
  • the compounds of the invention may be in protected forms, which include pharmaceutically-acceptable and cleavable ester forms, as well as protected forms used for organic synthesis, including, e.g. in protected forms as described in "Protective Groups in Organic Synthesis" by T. W. Greene and P. G. M. Wuts, 2nd Edition, 1991, John Wiley & Sons Inc., New York.
  • OH groups may be in protected form, e.g. in the form of silyl ethers (for instance as described in pages 68-86 of Greene and Wuts ibid.), esters (see e.g. pages 87-103 of Greene and Wuts ibid) and carbonates (see e.g. pages 104- 111 of Greene and Wuts ibid).
  • Suitable pharmaceutically acceptable salts for use in accordance with the invention include acid and base addition salts as appropriate having regard to the particular substituents present in the compound, e.g. HC1 salt forms.
  • the compounds of the invention include compounds in which the macrocylic ring is in ring open form.
  • the invention provides a compound of formula
  • Re is H or -C(O)-OR ⁇ o, wherein R i0 is H or Me;
  • R 9 is H or, when -a-b- is -(Me)CH-CH(OH)- and R is -C(O)-OMe, R 9 is Me, and
  • X is H when -N-_dN- represents a single bond between the two N atoms, or X together with -N--..- - represents a double bond between the two N atoms, in free or protected form or a salt thereof.
  • the compounds of formula I preferably compounds having spectra substantially as shown in Figures 2, 5, 8 and 1 1 , or 3, 6 and 9, or 20 and 30, or 21 and 31.
  • the invention provides compounds of formulae II (Decarboxy- seco-sanglifehrin A), ITJ (Seco-sanglifehrin A), IV (1-methoxy-seco-sanglifehrin A), V (Seco-sanglifehrin B) and VI (Seco-sanglifehrin C)
  • the compounds of the invention include compounds in which the l-oxo-7-aza- spiro- ⁇ 5,5 ⁇ -undecan-8-one-2-yl ring system is in ring open form.
  • the compounds of formula VII preferably include compounds having spectra substantially as shown in Figures 1, 4, 7 and 10, or 17 and 26.
  • the compounds of the invention also include compounds in which the 1 -oxo- 7-aza-spiro- ⁇ 5,5 ⁇ -undecan-8-one-2-yl ring system is in ring closed form and which are demethylated at the 43 position, i.e. the compounds of formulae X (Sanglifehrin G) and XI (Sanglifehrin H).
  • the compounds of the invention also include compounds in which the size of the macrocyclic ring has been increased or decreased, i.e.the compounds of formulae XJJ (Sanglifehrin F) and XDI (Sanglifehrin I),
  • the compounds of the invention include a compound in which the substitution pattern and alkcnc bond distribution within the macrocyclic ring are altered, i.e. the compound of formula XTV (Iso-sanglifehrin A)
  • the compounds of the invention also include a compound in which the carbonyl group at the S3 position has been reduced, i.e. the compound of formula XV (53-Dihydrosanglifehrin A).
  • the compounds of the invention also include the compound of formula XVI (SangUfehrin K)
  • the compounds of formulae I to XVI are useful intermediates for the preparation of sanglifehrins in general including ring closed forms and forms in which the size of the macrocyclic ring has been increased or decreased with respect to Sanglifehrin A.
  • Seco-sanglifehrins of the present invention may be prepared by cleavage of the macrolide ring of a ring closed sanglifehrin, e.g. Sanglifehrins A, B or C, at or in the vicinity of the lactone oxy group.
  • the compounds of formula III and IV may be prepared by treatment of sanglifehrin A under basic conditions, e.g. for the compound of formula III in the presence of an alkali metal hydroxide and e.g. for the compound of formula IV in the presence of methanol and an alkali metal carbonate.
  • the compounds of formulae VIII and IX may be obtained by cleavage of the spiro bicyclic ring system between the nitrogen atom and the central atom of the spiro system.
  • the compounds of formula I to XVI may be obtained as isolates from cultures of a sanglifehrin producing microorganism.
  • the compounds of formula I to XVI may be obtained as isolates from the cultures of Streptomyces sp. A92-308110 as hereinafter described.
  • the present invention also provides a process for the production of a compound of the invention as hereinbefore defined, which process comprises: i).
  • the compounds of the invention may be isolated from Streptomyces ⁇ p. A92- 308110. Samples of Streptomyces sp. A92-3081 10 were deposited with the Deutsche Sammlung von Mikroorganisrnen und Zellkulturen GmbH, Mascheroder Weg lb, D-38124 Braunschweig, Germany on the 3 May 1995 under the terms of the Budapest Treaty and have been assigned deposition number DSM 9954. Samples of Streptomyces ⁇ . A92- 308110 may also be obtained from Novartis AG CH-4002 Basel, Switzerland.
  • the characteristics, growth requirements and examples of ferrnentation procedures for Streptomyces ⁇ p_. A92-308110 are described in detail in WO 97 02285.
  • the compounds of the invention may exhibit some or all of the sanglifehrin characteristic activities and as such may find pharmaceutical uses all as described in WO 97/02285.
  • the invention also includes the use of the compounds of the invention as pharmaceuticals including methods of antiinflammatory or immunosuppresive treatment, pharmaceutical compositions containing the compounds of the invention and the use of the compounds of the invention for the preparation of antiinflammatory or immunosuppresive medicaments
  • Figure 2 shows the IR spectrum of Seco-sanglifehrin A
  • Figure 3 shows the IR spectrum of Seco-sanglifehrin B
  • FIG 4 shows the UV spectrum of Sanglifehrin E
  • FIG. 5 shows the UV spectrum of Seco-sanglifehrin A
  • Figure 6 shows the UV spectrum of Seco-sanglifehrin B
  • FIG. 7 shows the Mass spectrum of Sanglifehrin E
  • Figure 8 shows the Mass spectrum of Seco-sanglifehrin A
  • Figure 9 shows the Mass spectrum of Seco-sanglifehrin B
  • FIG. 10 shows the NMR spectrum of Sanglifehrin F
  • Figure 11 shows the NMR spectrum of Seco-sanglifehrin A
  • Figure 12 shows the Mass spectrum of Sanglifehrin F
  • Figure 13 shows the Mass spectrum of Sanglifehrin G
  • Figure 14 shows the Mass spectrum of Sanglifehrin H
  • Figure 15 shows the Mass spectrum of Sanglifehrin I
  • Figure 16 shows the Mass spectrum of Sanglifehrin K
  • Figure 17 shows the Mass spectrum of Sanglifehrin L
  • Figure 18 shows the Mass spectrum of 53-Dihydro-sanglifehrin A
  • Figure 19 shows the Mass spectrum of Iso-sanglifehrin A
  • Figure 20 shows the Mass spectmm of Seco-sanglifehrin C
  • Figure 21 shows the Mass spectrum of Decardoxyseco-sanglifehrin A
  • FIG. 22 shows the NMR spectrum of Sanglifehrin F
  • Figure 23 shows the NMR spectmm of Sanglifehrin G
  • Figure 24 shows the NMR spectrum of Sanglifehrin H
  • FIG. 25 shows the NMR spectrum of Sanglifehrin I
  • Figure 26 shows the NMR spectmm of Sanglifehrin K
  • Figure 27 shows the NMR spectrum of Sanglifehrin L
  • Figure 28 shows the NMR spectmm of 53-Dihydro-Sanglifehrin A
  • Figure 29 shows the NMR spectmm of Iso-sanglifehrin A
  • Figure 30 shows the NMR spectmm of Seco-sanglifehrin A
  • Figure 31 shows the NMR spectrum of Decarboxyseco-sangiifehrin A
  • the defatted extract ( 18 g) is chromatographed on 1 kg Sephadex LH20 to give a 3.5 g sanglifehrin-containing fraction. Separation on a column of 3 kg Lichroprep RP 18 Merck 40-60 ⁇ m with methanol/water (no pressure) yields 272 mg of a mixture of sanglifehrins. Further separation is done on a 20x20 cm preparative layer chromatography plate with methylene chloride/methanol/water 92:7.7:0.5 three times running. The plate is separated into three zones.
  • Sanglifehrin F (ms - Figure 12; NMR - Figure 22); Sanglifehrin G (ms - Figure 13; NMR - Figure 23); Sanglifehrin H (ms - Figure 14; NMR - Figure 24); Sanglifehrin I (ms - Figure 15 NMR - Figure 25); Sanglifehrin K (ms - Figure 16; NMR - Figure 26); Sanglifehrin L (ms - Figure 17; NMR - Figure 27); 53-Dihydrosanglifehrin A (ms - Figure 18; NMR - Figure 28); Iso-sanglifehrin A (ms - Figure 19; NMR - Figure 29); Seco-sanglifehrin C (ms - Figure 20; NMR - Figure 30), and Decarboxyseco-sangiifehrin A (ms - Figure 21; NMR - Figure 31).

Abstract

New macrolides of the Sanglifehrin class are provided, Sanglifehrins E, F, G, H, I, K and L, Seco-sanglifehrins A, B and C, 53-Dihydro-sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A and 1,-Methoxy-seco-sanglifehrin A, obtainable from fermentation broths of Streptomyces sp. A92-308110. The new macrolides are useful as intermediates for other Sanglifehrins.

Description

MACROLIDES
The present invention relates to macrohdes, in particular to new compounds belonging to the Sanglifehrin class of compounds.
The Sanglifehrins are a recently discovered class of macrolide compounds having immunosuppressive and antiinflammatory activities. The Sanglifehrins are generally described and claimed, together with their pharmaceutical uses, in our copending International Patent Application WO 97/02285, the relevant disclosure of which is incorporated herein by reference.
The Sanglifehrins have a characteristic polycyclic macrolide structure as may be seen, for instance, in the structure of Sanglifehrins A, one of the first Sanglifehrins to be isolated from actinomycete fermentation broths, shown below.
Figure imgf000003_0001
The characteristic structural features of the Sanglifehrins are discussed in detail in WO 97/02285.
In accordance with conventional practice in macrolide chemistry the atoms of the Sanglifehrin polycyclic ring system are numbered as indicated above for Sanglifehrin A, starting with the carbon atom of the carbonyl group of the macrocylic lactone linkage as position 1.
We have now isolated additional new sanglifehrins from actinomycete fermentation broths. Accordingly the present invention provides a Sanglifehrin selected from Sanglifehrins E, F, G, H, I, K and L, Seco-sanglifehrins A, B and C, 53-Dihydro- sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A and 1 ,-Methoxy- seco-sanglifehrin A in free or protected form or a salt thereof.
These novel Sanglifehrins are hereinafter referred to as the compounds of the invention.
Typically the compounds of the invention are in isolated form, or in pure or substantially pure form (i.e. in a form in which the sanglifehrin content thereof is at least 80%, preferably at least 90%, especially at least 95%, or more especially at least 98%, of the Sanglifehrin in question, e.g. in a form comprising less than 20%, preferably less than 10%, especially less than 5%, or more especially less than 2%, of other Sanglifehrins).
The compounds of the invention may be in protected forms, which include pharmaceutically-acceptable and cleavable ester forms, as well as protected forms used for organic synthesis, including, e.g. in protected forms as described in "Protective Groups in Organic Synthesis" by T. W. Greene and P. G. M. Wuts, 2nd Edition, 1991, John Wiley & Sons Inc., New York. In particular OH groups may be in protected form, e.g. in the form of silyl ethers (for instance as described in pages 68-86 of Greene and Wuts ibid.), esters (see e.g. pages 87-103 of Greene and Wuts ibid) and carbonates (see e.g. pages 104- 111 of Greene and Wuts ibid).
Compounds of the invention also exist in salt form. Examples of suitable pharmaceutically acceptable salts for use in accordance with the invention include acid and base addition salts as appropriate having regard to the particular substituents present in the compound, e.g. HC1 salt forms.
The compounds of the invention include compounds in which the macrocylic ring is in ring open form. Thus in particular embodiments the invention provides a compound of formula
Figure imgf000005_0001
wherein -a-b- is -(Me)C=CH- or -(Me)CH-CH(OH)-;
Re is H or -C(O)-ORιo, wherein Ri0 is H or Me;
R9 is H or, when -a-b- is -(Me)CH-CH(OH)- and R is -C(O)-OMe, R9 is Me, and
X is H when -N-_dN- represents a single bond between the two N atoms, or X together with -N--..- - represents a double bond between the two N atoms, in free or protected form or a salt thereof.
The compounds of formula I preferably compounds having spectra substantially as shown in Figures 2, 5, 8 and 1 1 , or 3, 6 and 9, or 20 and 30, or 21 and 31.
More particularly the invention provides compounds of formulae II (Decarboxy- seco-sanglifehrin A), ITJ (Seco-sanglifehrin A), IV (1-methoxy-seco-sanglifehrin A), V (Seco-sanglifehrin B) and VI (Seco-sanglifehrin C)
Figure imgf000006_0001
OH
Figure imgf000006_0002
Figure imgf000006_0003
Figure imgf000007_0001
The compounds of the invention include compounds in which the l-oxo-7-aza- spiro-{5,5 }-undecan-8-one-2-yl ring system is in ring open form.
Thus in particular embodiments the invention provides a compound of formula
VI.
Figure imgf000007_0002
wherein Rio is H or methyl, in free or protected form or a salt thereof.
The compounds of formula VII preferably include compounds having spectra substantially as shown in Figures 1, 4, 7 and 10, or 17 and 26.
More particularly the invention provides compounds of formulae VIII (Sanglifehrin E) and X (Sanglifehrin L)
Figure imgf000008_0001
Figure imgf000008_0002
The compounds of the invention also include compounds in which the 1 -oxo- 7-aza-spiro-{5,5 }-undecan-8-one-2-yl ring system is in ring closed form and which are demethylated at the 43 position, i.e. the compounds of formulae X (Sanglifehrin G) and XI (Sanglifehrin H).
Figure imgf000008_0003
OH
Figure imgf000009_0001
The compounds of the invention also include compounds in which the size of the macrocyclic ring has been increased or decreased, i.e.the compounds of formulae XJJ (Sanglifehrin F) and XDI (Sanglifehrin I),
Figure imgf000009_0002
Figure imgf000009_0003
The compounds of the invention include a compound in which the substitution pattern and alkcnc bond distribution within the macrocyclic ring are altered, i.e. the compound of formula XTV (Iso-sanglifehrin A)
Figure imgf000010_0001
The compounds of the invention also include a compound in which the carbonyl group at the S3 position has been reduced, i.e. the compound of formula XV (53-Dihydrosanglifehrin A).
Figure imgf000010_0002
OH
The compounds of the invention also include the compound of formula XVI (SangUfehrin K)
Figure imgf000011_0001
The compounds of formulae I to XVI are useful intermediates for the preparation of sanglifehrins in general including ring closed forms and forms in which the size of the macrocyclic ring has been increased or decreased with respect to Sanglifehrin A.
Seco-sanglifehrins of the present invention, i.e. the compounds of formula I, may be prepared by cleavage of the macrolide ring of a ring closed sanglifehrin, e.g. Sanglifehrins A, B or C, at or in the vicinity of the lactone oxy group. Thus, for example, the compounds of formula III and IV may be prepared by treatment of sanglifehrin A under basic conditions, e.g. for the compound of formula III in the presence of an alkali metal hydroxide and e.g. for the compound of formula IV in the presence of methanol and an alkali metal carbonate.
The compounds of formulae VIII and IX may be obtained by cleavage of the spiro bicyclic ring system between the nitrogen atom and the central atom of the spiro system.
More generally, the compounds of formula I to XVI may be obtained as isolates from cultures of a sanglifehrin producing microorganism. For example, the compounds of formula I to XVI may be obtained as isolates from the cultures of Streptomyces sp. A92-308110 as hereinafter described. Thus, in addition to the foregoing the present invention also provides a process for the production of a compound of the invention as hereinbefore defined, which process comprises: i). cultivating a Sanglifehrin E, F, G, H, I, K or , or Seco-sanglifehrins A, B or C, 53-Dihydro-sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A or 1 ,-Methoxy-seco-sanglifchrin A-producing actinomycete strain in a culture medium and isolating the desired Sanglifehrin E, F, G, H, I, K or , or Seco-sanglifehrins A, B or C, 53-Dihydro-sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A or 1,-Methoxy-seco-sanglifehrin A from the obtained culture broth;
ii). for the production of a compound of formula I, cleaving the macrocyclic ring of a corresponding ring closed Sanglifehrin at or in the vicinity of the lactone oxy group, and
ϋi). for the production of a compound of formula VTJ, cleaving the spiro bic lic ring system of a corresponding ring closed Sanglifehrin between the nitrogen atom and the central atom of the spiro sytem.
The compounds of the invention may be isolated from Streptomyces §p. A92- 308110. Samples of Streptomyces sp. A92-3081 10 were deposited with the Deutsche Sammlung von Mikroorganisrnen und Zellkulturen GmbH, Mascheroder Weg lb, D-38124 Braunschweig, Germany on the 3 May 1995 under the terms of the Budapest Treaty and have been assigned deposition number DSM 9954. Samples of Streptomyces β. A92- 308110 may also be obtained from Novartis AG CH-4002 Basel, Switzerland.
The isolation of compounds of the invention from cultures of Streptomyces sp. A92-308110 is described in Example 1.
The characteristics, growth requirements and examples of ferrnentation procedures for Streptomyces §p_. A92-308110 are described in detail in WO 97 02285. In addition to the use as intermediates for the preparation of other Sanglifehrins, the compounds of the invention may exhibit some or all of the sanglifehrin characteristic activities and as such may find pharmaceutical uses all as described in WO 97/02285.
Thus the invention also includes the use of the compounds of the invention as pharmaceuticals including methods of antiinflammatory or immunosuppresive treatment, pharmaceutical compositions containing the compounds of the invention and the use of the compounds of the invention for the preparation of antiinflammatory or immunosuppresive medicaments
The invention is further described by way of illustration only in the following Examples which refers to the accompanying Figures: in which Figure 1 shows the IR spectrum of Sanglifehrin E;
Figure 2 shows the IR spectrum of Seco-sanglifehrin A;
Figure 3 shows the IR spectrum of Seco-sanglifehrin B;
Figure 4 shows the UV spectrum of Sanglifehrin E;
Figure 5 shows the UV spectrum of Seco-sanglifehrin A;
Figure 6 shows the UV spectrum of Seco-sanglifehrin B;
Figure 7 shows the Mass spectrum of Sanglifehrin E;
Figure 8 shows the Mass spectrum of Seco-sanglifehrin A;
Figure 9 shows the Mass spectrum of Seco-sanglifehrin B;
Figure 10 shows the NMR spectrum of Sanglifehrin F;
Figure 11 shows the NMR spectrum of Seco-sanglifehrin A;
Figure 12 shows the Mass spectrum of Sanglifehrin F;
Figure 13 shows the Mass spectrum of Sanglifehrin G;
Figure 14 shows the Mass spectrum of Sanglifehrin H;
Figure 15 shows the Mass spectrum of Sanglifehrin I;
Figure 16 shows the Mass spectrum of Sanglifehrin K;
Figure 17 shows the Mass spectrum of Sanglifehrin L;
Figure 18 shows the Mass spectrum of 53-Dihydro-sanglifehrin A;
Figure 19 shows the Mass spectrum of Iso-sanglifehrin A; Figure 20 shows the Mass spectmm of Seco-sanglifehrin C;
Figure 21 shows the Mass spectrum of Decardoxyseco-sanglifehrin A;
Figure 22 shows the NMR spectrum of Sanglifehrin F;
Figure 23 shows the NMR spectmm of Sanglifehrin G;
Figure 24 shows the NMR spectrum of Sanglifehrin H;
Figure 25 shows the NMR spectrum of Sanglifehrin I;
Figure 26 shows the NMR spectmm of Sanglifehrin K;
Figure 27 shows the NMR spectrum of Sanglifehrin L;
Figure 28 shows the NMR spectmm of 53-Dihydro-Sanglifehrin A;
Figure 29 shows the NMR spectmm of Iso-sanglifehrin A;
Figure 30 shows the NMR spectmm of Seco-sanglifehrin A, and
Figure 31 shows the NMR spectrum of Decarboxyseco-sangiifehrin A;
EXAMPLES
Example 1 Isolation of compounds of the Invention from Streptomyces SP. A92-308110
Compounds of the invention are isolated from cultures of Streptomyces sp. A92-308110 analogously to the isolation of Sanglifehrins A, B, C and D as described in detail in WO 97/02285. The procedures and fermentation media used to prepare large scale cultures of sp. A92-308110 for isolation of the compounds of the invention are essntially as described in WO 97/02285.
A. Sanglifehrin E
During the large scale fermentation and purification of Sanglifehrin A as described in WO 97/02285, 91 g of crude product obtained from the Sephadex column is chromatographed on a column of 1 kg Silicagel Merck 0.040 to 0.063 μm with hexane : acetone 7:3, 5:5, 3:7, 2:8, 1 :9, acetone and methanol. Fractions of 2 1 are collected. The fractions containing the sanglifehrins, fractions 4 to 6 21.3 g, are further separated on a column of 3 kg Lichroprep RP18 Merck, with methanol/water 8:2. Beside the fractions with Sanglifehrin A and Sanglifehrin B, fraction 3, 1.6 g is analysed by HPLC and TLC and found to contain a new sanglifehrin-like compound. Final purification, on a column of 100 g Silicagel H with ethyl acetate saturated with water as eluent, yields 360 mg sanglifehrin E. mp.l31-135°C amorph, (α)o20 = -55.7° (c= 0.998, methanol). The IR-, UV-, MS- and NMR spectra of this product are given in figures 1, 4, 7 and 10 respectively.
B. Secosanglifehrin A
670 g defatted extracts from two 3000 1 fermentations, as described in WO 97/02285, are chromatographed on 10 kg Sephadex LH20 with methanol. The sanglifehrin containing fractions are combined to give 150 g of crude product. Further chromatography on 1 kg Silicagel Merck MTBE, MTBE 10% methanol elutes Sanglifehrins A and B. Washing of the column with 5 1 methanol yields 71 g fraction 1 1.
15 g of this fraction are further chromatographed on 150 g Silicagel with ethyl acetate/ ethanol 95:5, 90: 10, 85: 15, 80:20, 70:30 and fractions of 1 1 collected. Fractions 6 to 8 are combined (5.7 g) and further purified by chromatographic steps on 3 kg Lichroprep RP18 with methanol/water 75:25 and 1 kg Sephadex LH20 in methanol to give 51 1 mg pure secosanglifehrin A. The IR-, UV-, MS- and NMR- spectra of this product are given as Figures 2, 5, 8 and 1 1 respectively.
C. Secosanglifehrin B
From two 50 1 fermentations, the defatted extract ( 18 g) is chromatographed on 1 kg Sephadex LH20 to give a 3.5 g sanglifehrin-containing fraction. Separation on a column of 3 kg Lichroprep RP 18 Merck 40-60 μm with methanol/water (no pressure) yields 272 mg of a mixture of sanglifehrins. Further separation is done on a 20x20 cm preparative layer chromatography plate with methylene chloride/methanol/water 92:7.7:0.5 three times running. The plate is separated into three zones. The most polar zone is eluted with methanol and once more chromatographed on a preparative layer chromatography plate with methylene chloride/methanol/water 80: 17.5:2. The zone with the new compound is eluted to yield 30 mg of secosanglifehrin B. The IR-, UV- and MS-spectra of this product are given as Figures 3, 6 and 9 respectively.
Analogously the further compounds of the invention are isolated from fermentation broths of Streptomyces sp. A92-308110:
Sanglifehrin F (ms - Figure 12; NMR - Figure 22); Sanglifehrin G (ms - Figure 13; NMR - Figure 23); Sanglifehrin H (ms - Figure 14; NMR - Figure 24); Sanglifehrin I (ms - Figure 15 NMR - Figure 25); Sanglifehrin K (ms - Figure 16; NMR - Figure 26); Sanglifehrin L (ms - Figure 17; NMR - Figure 27); 53-Dihydrosanglifehrin A (ms - Figure 18; NMR - Figure 28); Iso-sanglifehrin A (ms - Figure 19; NMR - Figure 29); Seco-sanglifehrin C (ms - Figure 20; NMR - Figure 30), and Decarboxyseco-sangiifehrin A (ms - Figure 21; NMR - Figure 31).
Example 2 - Conversion of Sanglifehrin A into the ring-open compounds of Formula IV and III
Figure imgf000017_0001
Figure imgf000017_0002
20 mg of Sanglifehrin A is dissolved in 0.5 ml of methanol and 3 mg of K2CO3. The resultant yellow coloured solution is stirred at room temperature for 1 hour, and then left to stand at room temperature for 3 days. After washing and evaporation of solvent, the compound of formula IV is purified by silica gel chromatography (90:10 CH2Cl2:MeOH). CβHosNjOu; MW = 1122.46; MS : BT10/818/1 : ML+ : 1128.
20 mg of Sanglifehrin A is dissolved in 95 ml of THF and 100 μl of IN NaOH is added. The resultant yellow solution is stirred at room temperature for 1 hour and left to stand at room temperature for 3 days. After washing and evaporation of solvent, the compound of formula III is purified by reverse phase chromatography (30:70 CHjCN: H2O - 100 CH3CN over 40 min). C60H93N5O14; MW = 1 108.44. see also spectra given in Figures 2, 5, 8 and 1 1.
INDICATIONS RELATING TO A DEPOSITED M'r,»nORr.AMW
(PCT Rule \3bιs)
A. The indications made below relate to the microorganism reierred to in the description on page l rj . line 1 7 — 2 2
B. IDENTIFICATION OK DEPOSIT Further deposits are identified on an additional sheei | |
Name ol depositary institution
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Address ol depositary institution πncludtnt; postal code and counmi
Mascheroder Weg 1 b D 38124 Braunschweig GERMANY
Date ol deposit Accession Number
3 May 1 995 DSM 9954
C. ADDITIONAL INDICATIONS l leave blank if not applicable: This information is continued on an additional sheet | |
We request the Expert Solution where available.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE til the indications are not lor all designated S iesi
E. SEPARATE FURNISHING OF INDICATIONS Heave blank it not applicable)
The indications listed below will be submined to the International Bureau later i spent ilie general nature m the indications <■ ; Accession Number f Deposit' I
For rcce πe Office use only For International Bureau use onlv
1 1 This sheet was received with the international application j I This sheet was received by the International Bureau on:
Authorized officer fit** Authorized officer rt.LR. Pβthβr
Form PCT/RO/134 (July 1992)

Claims

A Sanglifehrin selected from the group consisting of Sanglifehrins E, F, G, H, I, K and L, Seco-sanglifehrins A, B and C, 53-Dihydro-sanglifehrin A, Iso- sanglifehrin A, Decarboxy-seco-sanglifehrin A and 1 ,-Methoxy-seco- sanglifehrin A in free or protected form or a salt thereof.
A compound of formula I
Figure imgf000020_0001
wherein -a-b- is -(Me)C=CH- or -(Me)CH-CH(OH)-;
Rg is H or -C(O)-ORιo, wherein R|0 is H or Me;
R9 is H or, when -a-b- is -(Me)CH-CH(OH)- and R is -C(O)-OMe, R9 is Me, and
X is H when -N-_J^- represents a single bond between the two N atoms, or X together with -N---iN- represents a double bond between the two N atoms, in free or protected form or a salt thereof.
A compound according to claim 2 which is Decarboxy-seco-sanglifehrin A, Seco-sanglifehrin A, 1-methoxy-seco-sanglifehrin A, Seco-sanglifehrin B or Seco-sanglifehrin C.
A compound of formula VI.
Figure imgf000021_0001
wherein Rio is H or methyl, in free or protected form or a salt thereof.
5. A process for the production of a compound of the invention as hereinbefore defined, which process comprises: i). cultivating a Sanglifehrin E, F, G, H, I, K or L, or Seco-sanglifehrins A, B or C, 53-Dihydro-sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A or 1 ,-Methoxy-seco-sanglifehrin A-producing actinomycete strain in a culture medium and isolating the desired Sanglifehrin E, F, G, H, I, K or L, or Seco-sanglifehrins A, B or C, 53-Dihydro-sanglifehrin A, Iso-sanglifehrin A, Decarboxy-seco-sanglifehrin A or 1 ,-Methoxy-seco-sanglifehrin A from the obtained culture broth;
ii). for the production of a compound of formula I as defined in claim 2, cleaving the macrocyclic ring of a corresponding ring closed Sanglifehrin at or in the vicinity of the lactone oxy group, and
iii). for the production of a compound of formula VII as defined in claim 4, cleaving the spiro bicylic ring system of a corresponding ring closed Sanglifehrin between the nitrogen atom and the central atom of the spiro sytem.
6. The use of a compound according to claim 1 as an intermediate for preparation a further Sanglifehrin.
7. The use of a compound as defined in claim 1 as a pharmaceutical, e.g. for antiinflammatory or immunosuppressive uses.
8. A pharmaceutical composition containing a compound as defined in claim 1.
9. The use of a compound as defined in claim 1 , for the preparation of an antiinflammatory or immunosuppresive medicament.
PCT/EP1997/004563 1996-08-22 1997-08-21 Macrolides WO1998007743A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43807/97A AU4380797A (en) 1996-08-22 1997-08-21 Macrolides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70160496A 1996-08-22 1996-08-22
US08/701,604 1996-08-22
US08/774,114 US6124453A (en) 1995-07-04 1996-12-24 Macrolides
US08/774,114 1996-12-24

Publications (1)

Publication Number Publication Date
WO1998007743A1 true WO1998007743A1 (en) 1998-02-26

Family

ID=27106817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004563 WO1998007743A1 (en) 1996-08-22 1997-08-21 Macrolides

Country Status (3)

Country Link
US (1) US6124453A (en)
AU (1) AU4380797A (en)
WO (1) WO1998007743A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062540A1 (en) * 1998-06-02 1999-12-09 Novartis Ag Use of cyclosporins in the treatment of inflammatory autoimmune diseases
WO2006138507A1 (en) 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
WO2010034243A1 (en) 2008-09-24 2010-04-01 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
CN101691575A (en) * 2008-09-24 2010-04-07 中国科学院上海有机化学研究所 Biosynthetic gene cluster of sanglifehrin
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011144924A1 (en) 2010-05-17 2011-11-24 Biotica Technology Limited Amine or amid analogues of sanglifehrin
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN102260644A (en) * 2011-07-14 2011-11-30 中国科学院上海有机化学研究所 Mutant strain of Streptomyces flaveolus and construction method and application thereof
WO2012078915A1 (en) 2010-12-10 2012-06-14 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2012085553A1 (en) 2010-12-20 2012-06-28 Biotica Technology Limited Sanglifehrin derivatives and methods for their production
WO2012131371A1 (en) 2011-03-29 2012-10-04 Biotica Technology Limited Macrocyclic compound and methods for its production
WO2013061052A1 (en) 2011-10-24 2013-05-02 Biotica Technology Limited Novel dosage form
WO2013185090A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185093A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US9989535B2 (en) * 2015-10-01 2018-06-05 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
US10203323B2 (en) 2010-12-28 2019-02-12 Warp Drive Bio, Inc. Identifying new therapeutic agents
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US10907188B2 (en) 2016-04-12 2021-02-02 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11479797B2 (en) 2016-10-28 2022-10-25 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001510838A (en) * 1997-07-25 2001-08-07 アメリカ合衆国 Macrocyclic lactones, compositions and methods of use
EP1483251B1 (en) 2002-03-12 2009-12-23 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
JP4928261B2 (en) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド Macrocyclic antagonist of motilin receptor
FR2908658B1 (en) * 2006-11-20 2011-11-11 Centre Nat Rech Scient COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF DISEASES ASSOCIATED WITH OVEREXPRESSION OF TNF AND / OR IL-12
CN101289440B (en) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 Polyene macrocyclic compounds, preparation thereof and applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006649A1 (en) * 1993-09-01 1995-03-09 Sandoz Ltd. Macrolides as antagonists of macrophilin binding immunosuppressants
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
WO1997002285A1 (en) * 1995-07-04 1997-01-23 Novartis Ag Macrolides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006649A1 (en) * 1993-09-01 1995-03-09 Sandoz Ltd. Macrolides as antagonists of macrophilin binding immunosuppressants
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
WO1997002285A1 (en) * 1995-07-04 1997-01-23 Novartis Ag Macrolides

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062540A1 (en) * 1998-06-02 1999-12-09 Novartis Ag Use of cyclosporins in the treatment of inflammatory autoimmune diseases
WO2006138507A1 (en) 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
CN101691575A (en) * 2008-09-24 2010-04-07 中国科学院上海有机化学研究所 Biosynthetic gene cluster of sanglifehrin
WO2010034243A1 (en) 2008-09-24 2010-04-01 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
CN102224242B (en) * 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 Novel gene cluster
CN101691575B (en) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 Biosynthetic gene cluster of sanglifehrin
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
CN102770139A (en) * 2010-02-09 2012-11-07 百奥帝卡技术有限公司 Sanglifehrin based compounds
WO2011144924A1 (en) 2010-05-17 2011-11-24 Biotica Technology Limited Amine or amid analogues of sanglifehrin
WO2012078915A1 (en) 2010-12-10 2012-06-14 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2012085553A1 (en) 2010-12-20 2012-06-28 Biotica Technology Limited Sanglifehrin derivatives and methods for their production
EP3427737A1 (en) 2010-12-20 2019-01-16 NeuroVive Pharmaceutical AB Sanglifehrin derivatives and methods for their production
US11644460B2 (en) 2010-12-28 2023-05-09 Revolution Medicines, Inc. Identifying new therapeutic agents
US10989710B2 (en) 2010-12-28 2021-04-27 Revolution Medicines, Inc. Identifying new therapeutic agents
US10203323B2 (en) 2010-12-28 2019-02-12 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2012131377A1 (en) 2011-03-29 2012-10-04 Biotica Technology Limited Macrocyclic compounds and methods for their production
WO2012131371A1 (en) 2011-03-29 2012-10-04 Biotica Technology Limited Macrocyclic compound and methods for its production
CN102260644B (en) * 2011-07-14 2013-06-05 中国科学院上海有机化学研究所 Mutant strain of Streptomyces flaveolus and construction method and application thereof
CN102260644A (en) * 2011-07-14 2011-11-30 中国科学院上海有机化学研究所 Mutant strain of Streptomyces flaveolus and construction method and application thereof
WO2013061052A1 (en) 2011-10-24 2013-05-02 Biotica Technology Limited Novel dosage form
USRE47334E1 (en) 2012-06-08 2019-04-02 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185093A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
EP3392253A1 (en) 2012-06-08 2018-10-24 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US9642889B2 (en) 2012-06-08 2017-05-09 Gilead Sciences, Inc. Macrocyclic inhibitors of Flaviviridae viruses
US9512175B2 (en) 2012-06-08 2016-12-06 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US10246486B2 (en) 2012-06-08 2019-04-02 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2013185090A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US9873716B2 (en) 2012-06-08 2018-01-23 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US10472392B2 (en) 2012-06-08 2019-11-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US11059830B2 (en) 2015-01-09 2021-07-13 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US10466249B2 (en) 2015-10-01 2019-11-05 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces
US10948495B2 (en) 2015-10-01 2021-03-16 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces
US9989535B2 (en) * 2015-10-01 2018-06-05 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
US10907188B2 (en) 2016-04-12 2021-02-02 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11447810B2 (en) 2016-04-12 2022-09-20 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11479797B2 (en) 2016-10-28 2022-10-25 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
US11952352B2 (en) 2019-11-04 2024-04-09 Revolution Medicines, Inc. Ras inhibitors
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
AU4380797A (en) 1998-03-06
US6124453A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
WO1998007743A1 (en) Macrolides
AU708004B2 (en) Macrolides
Tomoda et al. Pyripyropenes, novel AC AT inhibitors produced by Aspergillus fumigatus III. Structure elucidation of pyripyropenes E to L
EP0926242A1 (en) Gliotoxin derivatives and anticancer agent comprising the same
US4738958A (en) Ansamycin antibiotic and its use as a medicament
US4945108A (en) Angucyclinones from streptomycetes, a process for the preparation thereof, and the use thereof
CA1206111A (en) Physiologically active substance p-23924, its production and use
Michel et al. NEW AZASTEROIDAL ANTIFUNGAL ANTIBIOTICS FROM GEOTRICHUM FLAVO-BRUNNEUM II. ISOLATION AND CHARACTERIZATION
AU2001266206B2 (en) Polycyclic xanthones as antibiotics
AU689207B2 (en) Indole diterpene alkaloid compounds
US4199514A (en) Compound, frenolicin B which is useful as an antibiotic
US5100921A (en) Angucyclinones from streptomycetes, a process for the preparation thereof, and the use thereof
Kleinwaechter et al. Spirobenzofuran, a new bioactive metabolite from Acremonium sp. HKI 0230
Carreras et al. Hydroxylation of sodic grindelate by Cunninghamella echinulata
EP0768317B1 (en) UCK14 compounds
US4912133A (en) BU-3862T antitumor antibiotic
Choudhary et al. Microbial transformations of gelomulide G: A member of the rare class of diterpene lactones
JP3124373B2 (en) Immunosuppressant
WO2004101502A1 (en) Polyene polyketides, processes for their production and their use as pharmaceuticals
García-Granados et al. New polyoxygenated ent-manoyl oxides obtained by biotransformation with filamentous fungi
US4695544A (en) Process for the preparation of cholecystokinin antagonists
JP2001247574A (en) Physiologically active substance gkk1032 compound
US5093248A (en) BU-3862T antitumor antibiotic
US5252472A (en) Process for the production of furans and lactones from streptomyces
US4463182A (en) Antibiotic roridin E-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998510424

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase